anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: A low Glasgow Coma Scale Score (GCS) on admission is a known predictor of poor outcome from childhood bacterial meningitis. In turn, the factors associated with the admission GCS are less known. Our aim was to identify them, both for clinical alerts of reserved prognosis and to find potential targets for intervention.
METHODS: This study is a secondary analysis of data collected prospectively in Angola and in Latin America between 1996 and 2007. Children with bacterial meningitis were examined on hospital admission and their GCS was assessed using the age-adjusted scale. Associations between on-admission GCS and host clinical factors were examined.
RESULTS: A total of 1376 patients with confirmed bacterial meningitis were included in the analysis (609 from Latin America and 767 from Angola). The median GCS was 13 for all patients (12 in Angola and 13 in Latin America). In the multivariate analysis, in the areas combined, seizures, focal neurological signs, and pneumococcal aetiology associated with GCS <13, as did treatment delay in Latin America.
CONCLUSION: Besides pneumococcal aetiology, we identified characteristics, easily registrable on admission, which are associated with a low GCS in childhood bacterial meningitis. Of these, expanding pneumococcal vaccinations and treatment delays could be modified.
PURPOSE: To compare the rotational stability of a monofocal and a diffractive multifocal toric intraocular lens(IOLs) with identical design and material.
METHODS: This prospective study enrolled patients who underwent plate-haptic toric IOL (AT TORBI 709 M and AT LISA 909 M) implantation. Propensity score matching (PSM) was performed to balance baseline factors. Follow-up examinations were conducted at 1 h, 1 day, 3 days, 1 week, 2 weeks, 1 month, and 3 months postoperatively. A linear mixed model of repeated measures was used to investigate the changes in IOL rotation over time. A 2-week timeframe was utilized to assess differences in IOL rotation between the two groups.
RESULT: After PSM, a total of 126 eyes were selected from each group for further analysis. Postoperatively, the time course of IOL rotation change in the two groups remained consistent, with the greatest rotation occurring between 1 h and 1 day postoperatively. At the 2-week postoperative mark, the monofocal toric IOL exhibited a higher degree of rotation compared to the multifocal toric IOL (5.40 ± 7.77° vs. 3.53 ± 3.54°, P = 0.015). In lens thickness(LT) ≥ 4.5 mm and white-to-white distance(WTW) ≥ 11.6 mm subgroups, the monofocal toric IOL rotated greater than the multifocal toric IOL (P = 0.026 and P = 0.011, respectively).
CONCLUSION: The diffractive multifocal toric IOL exhibits superior rotational stability compared to the monofocal toric IOL, especially in subgroups LT ≥ 4.5 mm and WTW ≥ 11.6 mm. Moreover, the time course of IOL rotation change is consistent for both, with the maximum rotation occurring between 1 h and 1 day postoperatively.
Growing evidence indicates that aberrant DNA hypermethylation is associated with leukemia development, drug resistance, and relapse. It has been shown that pretreating leukemia cells with AZA or decitabine could partially reverse the aberrant DNA methylation, restore the expression of tumor suppressor gene important for apoptosis, and sensitize cells to subsequent killing by cytotoxic agent. Since cytarabine and decitabine share the same mechanisms of resistance, we use AZA to test the novel epigenetic "priming" approach. This is a phase I clinical study with expansion phase, using hypomethylating agent, 5-azacytidine (AZA), in sequential with chemotherapy to evaluate whether epigenetic "priming" can reverse aberrant DNA methylation, overcome drug resistance, and increase response in relapsed/refractory AML.

The chemotherapy regimen to be used in this study is fludarabine and cytarabine. This regimen has substantial activity in leukemia and has been widely used in treating pediatric patients with relapsed/refractory AML and ALL in the past several decades. In BFM relapsed AML 2001/01 study, FLAG (fludarabine, cytarabine and G-CSF) chemotherapy regimen showed significant activity in AML with 4 year OS around 36%. Since the use of G-CSF in conjunction with fludarabine/cytarabine didn't improve the overall survival of patient in a randomized trial, only fludarabine and cytarabine will be used in this study to decrease the incidence of leukocytosis related complications. This regimen is very similar to the chemotherapy regimen proposed for the next relapsed AML trial within the Children's Oncology Group (COG). If this trial proves to be safe and active, it will provide the foundation and smooth transition to larger statistically powered nationwide phase II clinical trials by COG.
The study will be carried out in an area around Lake Victoria in Kenya where the prevalence of schistosomiasis and malaria are highest in the areas nearest to the Lake. Depending on the prevalence of schistosomiasis a sample of between 876 to 2.524 children will be enrolled in the study. The children who will be in the age between 9 to 12 year, will have their stool and urine examined for schistosomiasis and intestinal worms and a blood sample will be examined for malaria parasites and the hemoglobin level. Children will also be weight, measured and examined by a doctor and register their food intake over one week, to determine their nutritional status. Children who are found to be infected with schistosomiasis, intestinal worms or malaria will be offered treatment. Children who are found to have anemia will be offered a course of iron supplementation, children with severe anemia will be referred to the nearest health facility for treatment. 12 months after the initial examinations and treatment all children will have a re-examination of their stool, urine and blood.
A double-blind, randomized, crossover study comparing the effects of tocotrienols vs. placebo will be conducted in subjects with metabolic syndrome. Subjects will be supplemented with Tocovid Suprabio 200 mg twice daily (or placebo) for 2 weeks followed by a postprandial challenge on Day 14. During the postprandial challenge, venous blood samples will be collected during fasting. Subjects are then required to consume a high fat breakfast meal containing 50g fat and 100mL milkshake, followed by the assigned capsules. Venous blood samples will be drawn at 2, 4 and 6 hours after consumption of capsules. A washout period of at least 14 days will be in place before the commencement of the second treatment.
Fit \& Strong! Plus differs from Fit \& Strong! only in that the 30 minutes of health education, while retaining the core physical activity and osteoarthritis components, has weight and diet-related topics added to the curriculum.
The OBA group will be administered a saline infusion at the same rate of the ketamine infusion (only while in the PACU) up until PACU discharge so that surgeons, patients, and PACU nurses will be blinded. The OBA group will be administered fentanyl 100 mcg IV for anesthesia induction followed by 50 mcg IV boluses when heart rate or systolic blood pressure is 20% above baseline throughout the case.
This phase 1, single cohort study will enroll up to 10 healthy subjects. All subjects will be pre-screened for eligibility. If the subject meets eligibility for study participation, informed consent will be obtained. Screening will include a history and physical, review of concomitant medications, assessment of NYHA functional status, assessment of ECOG performance status, clinical laboratory tests, pregnancy test (for women of child-bearing abilities), assessment of peripheral venous access, and a donor history questionnaire (DHQ). If subjects meet eligibility criteria, they will be asked to undergo two apheresis collections and donate their mononuclear cells (MNCs) for research purposes.

Subjects will be scheduled for the first apheresis collection on study Day 1. Two total blood volume (TBV) will be processed during each apheresis collections, which is currently the collection centers standard practice. All subjects will receive N-803 at a fixed dose of 1 mg by subcutaneous (SC) injection 4 to 5 days prior to the second apheresis collection. The N-803 dose may be administered starting on study Day 8 but no later than study Day 24. The study day for N-803 administration will be determined based on the planned date of the second apheresis collection. The second apheresis collection should occur between study Day 12 and study Day 29. Two TBV will be processed during this collection.

Subjects will be followed for collection of adverse events (AEs) from study Day 1 (first apheresis collection) through the end of study (EOS) visit. Subjects will be instructed to contact the study team in the event they experience AEs post N-803 administration (e.g., injection site reaction). In addition, AEs will be elicited from subjects during follow-up phone calls.
A computer implemented medical record database management system including access by individual patients. A healthcare product or service advertiser can send one or more advertisements to a central server. These advertisements can include, but are not limited to, healthcare products and/or services, medical products and/or services, prescriptions for pharmaceuticals, non-prescription medicines, etc. Each advertisement is linked to one or more key words. These key words generally reference medical conditions. These keys may also relate to pharmaceuticals or other healthcare descriptions. Scripts may also be used in addition to keys to enable more complex correlations of a medical condition or combination of conditions or health information to a particular advertisement. The advertisements may be accessed by individual patients.
Doublet combination dose escalation of PF-07265807 with sasanlimab in participants with select tumor types. PF-07265807 will dose escalate. Sasanlimab dose will stay constant.
This invention belongs to mutation or genetic engineering field, which discloses a preparation of low antigen mutation of staphylokinase and its usage. The front six amino acids of SAK have nothing with thrombolytic activity, but it can influence their stability in some prokaryotic cells. Meanwhile, the segment where 35,74,80,82,130,135 and 136 amino acid exist has lots of B-lymphocyte epi-position, therefore, removing the front six amino acids of SAK, constructing N-terminal deletion, SAK mutant of the intermediate and C-terminal segments multi-point modified by the methods of fragments missing, point mutation and so on. Although there is no significant change with thrombolytic activity of the mutant, antigenicity of the mutant decreases significantly. The mutant of this invention fits for expression and the preparation in the prokaryotic cell, bringing the convenience for industry. Its biological activity has no significant   difference compared with wild type, so the mutant can apply for dissolving internal clot, and its characteristic of decreasing antigenicity degradation may make it possible for application many times.
148,202. Strubell, A. Dec. 28, 1914, [Convention date]. Bacteria, cultivating; vaccines.-Tubercle bacilli and other acid-resisting bacteria are cultivated, as described in Specification 172,030 with reference to non acid-resistant bacteria, on a bouillon containing over two per cent of sugar and are treated, to obtain partial antigens, with phenol solutions at high temperature. The bouillon is prepared from meat extract or veal or beef, cooked, filtered, sterilized, and mixed with peptone and salt, and then with sugar. Glucose may be used in the proportion of 2 to 6 per cent, and saccharose up to 12 per cent. Bacilli, separated from the culture medium, are treated in a series of stages with 2 to 10 per cent phenol solution, and at one stage are allowed to stand in such solution for 3 to 5 months at a temperature of 37-58‹ C. Matter passing into solution is discarded and the remaining opened-up bacterial mass is suspended in sodium chloride solution containing 0.5 per cent phenol as a preservative. The Specification as open to inspection under Sect. 91 (3) (a) contains also the subject-matter of Specification 172,030 and relates to the use of the various antigens and vaccines obtained for the direct immunization of human beings or animals, or for injection into animals during a period of months for obtaining sera rich in anti-bodies. It relates also to the treatment of human tuberculosis by the simultaneous injection of a lipoid serum and a serum containing anti-bodies active against tuberculo-albumin so that the intoxication caused by the action of the lipoid serum is reduced. This subject-matter does not appear in the Specification as accepted.
Biofeedback. Participants receiving the HRV-B intervention will complete a baseline assessment, a minimum of 4 weeks and up to 6 weekly training sessions (until the criterion of HRV coherence is met), and a final appointment (3-7 days later) where post-training HRV and symptom inventories will be recorded.
It is intended to develop a film agent made of a novel amphoteric urethane resin and apply to cosmetics, in particular, hair cosmetics and external preparations for the skin. Namely, cosmetics characterized by containing an amphoteric urethane resin carrying a polysiloxane compound. The amphiphilic urethane resin as a constituent of the amphiphilic urethane resin carrying a polysiloxane compound employed in a cosmetic formulation of the invention is preferably an amphiphilic urethane resin formed by reacting at least compounds (A) to (D): (A) a polyol compound; (B) a polyisocyanate compound; (C) a compound having at least one group selected from a hydroxyl group, primary amino group and secondary amino group and also having a carboxyl group; and, (D) a compound having at least one group selected from a hydroxyl group, primary amino group and secondary amino group and also having a tertiary amino group. Thus excellent cosmetics which can fully exert the film properties of the novel polysiloxane-carrying amphoteric urethane resin can be obtained. In case of hair cosmetics, for example, a favorable elasticity of the hair and excellent brushing properties without causing flaking can be established. In case of skin cosmetics, a moist and smooth feel and an appropriate elasticity can be imparted to the skin.
We propose to conduct an amodiaquine-artesunate efficacy trial at Bondo District Hospital in Kenya. The results will enable us to better interpret the results of the main IPTi trial. We will assess the efficacy of a three day course of amodiaquine plus three days of artesunate (AQ3/AS3) for the treatment of symptomatic, uncomplicated P. falciparum infections. Study subjects are febrile children, 6-59 months old, with laboratory-confirmed uncomplicated P. falciparum infections. Clinical and parasitological parameters will be monitored over a 28-day follow-up period to evaluate drug efficacy. Children will be followed closely for signs of drug failure or recrudescence, and any children failing therapy will be treated with Coartem or, if severe, with quinine. We will also perform drug resistance testing on parasite samples from children with treatment failure. The results of this efficacy trial will allow us to assist policymakers in deciding what drugs should be used for IPTi, should it be adopted into national policy.
The present invention is to provide a cream-like solid agarose-in-water gel particles two-phase suspension useful for cosmetics applications, wherein the suspension is an intermediate cosmetics product. The agarose-in-water gel particles serve as a moisturizing agent, i.e. they deliver water to the skin, and impart the skin feel to the final cosmetics product. The cream-like suspension complies with ASTM skin feel analysis, which is separated in to three main evaluation sections: evaluation of the product in a petri dish, pick-up evaluation, and rub out evaluation. In the preferable embodiments the continuous phase is a water immiscible phase selected from the groups consisting of esters of the general formula RCO-OR′ and tri, di, and mono-glycerides of fatty acids. The agarose particles can be prepared from natural agarose, reduced agarose or synthetically substituted agarose.
Exemplary embodiments may provide a user interface and logic for assisting a user in calculating a proper medicament bolus dosage. The user interface may be simple and easy to understand. The user interface may clearly specify needed inputs, such as a carbohydrates amount for a meal that is about to be ingested and the current glucose level reading for the user. Entered inputs may be displayed on the user interface. The user interface may depict key calculated values resulting from calculations that involve the inputs, including the total bolus dosage calculation. The user interface also may depict the values that contribute to the total bolus dosage calculation. Some of the input values, such as carbohydrates amount, may be prepopulated by the management device or medicament delivery device. The user interface may permit overriding of prepopulated input values.
Participants receive active asenapine 2.5 mg tablets sublingually BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive active asenapine 5.0 mg tablets sublingually BID for the remainder of the 8-week treatment period.
Patients will be admitted to a dedicated nursing unit for HD aldesleukin administration. Patients will receive bolus aldesleukin at a dose of 600,000 IU/Kg every eight hours on days 1-5 with a goal of 10-12 doses.
Hyoscyamine sulfate Injection, USP is effective as adjunctive therapy in the treatment of peptic ulcer. In acute episodes, Hyoscyamine sulfate Injection, USP can be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Parenterally administered Hyoscyamine sulfate Injection, USP is also effective in reducing gastrointestinal motility to facilitate diagnostic procedures such as endoscopy or hypotonic duodenography. Hyoscyamine sulfate Injection, USP may be used to reduce pain and hypersecretion in pancreatitis, in certain cases of partial heart block associated with vagal activity, and as an antidote for poisoning by anticholinesterase agents.

In Anesthesia:

Hyoscyamine sulfate Injection, USP is indicated as a pre-operative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and acidity of gastric secretions, and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. Hyoscyamine sulfate Injection, USP protects against the peripheral muscarinic effects such as bradycardia and excessive secretions produced by halogenated hydrocarbons and cholinergic agents such as physostigmine, neostigmine, and pyridostigmine given to reverse the actions of curariform agents.

In Urology:

Hyoscyamine sulfate Injection, USP may also be used intravenously to improve radiologic visibility of the kidneys. It is also indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic.
FIELD: virology. SUBSTANCE: invention relates to method of preparing the vaccine strain preparation of cucumber mottle virus. Vaccine is prepared by infection of cucumber growing seedlings at the stage of 1-3 true leaves with the diluted virus suspension at concentration 10- 10mcg/ml. Then plants were grown and the infected symptomless plants were selected using serological tests. Plant sap is prepared from these plants, plant proteins were coagulated by heating at 60 C and preparation is isolated by precipitation with ammonium sulfate. Precipitate is placed on paper filter and virus is washed out. Preparation can be used for plant protection for viral epiphytoty control. EFFECT: improved efficiency.
Based on the clinical efficacy of ALK inhibitors in ALK+NSCLC, NCCN guidelines recommend ALK molecular testing of lung cancer patients, to select patients for ALK-targeted therapy. However, molecular testing via tissue biopsy cannot always be performed on NSCLC patients, potentially limiting access of effective treatment to the subset of patients who are able to undergo current testing procedures that utilize tissue biopsies. Obtaining an adequate tissue biopsy specimen for NSCLC presents a number of challenges. In particular, the method for diagnosis of lung cancer depends on the location, size, and type of suspected lung cancer, and the presence or absence of metastases. Common procedures for centrally located tumors include bronchoscopy and sputum cytology, which frequently yield insufficient tumor tissue for comprehensive mutation testing. In addition, 75% of patients are diagnosed with late-stage disease and often present with multiple comorbidities. Biopsies in these patients can lead to complications such as pneumothorax, hemoptysis, other bleeding complications, and cardiopulmonary decompensation. As a result of these factors, a physician treating a patient who presents with a significant burden of disease as well as significant comorbidities may rightly consider whether it is in the best interest of the patient to undergo a risky and potentially unsuccessful procedure. Thus, there exists a major unmet clinical need for testing procedures that do not require tumor tissue. The purpose of this phase II study is to assess the efficacy of brigatinib in patients with advanced NSCLC harboring ALK rearrangement that are selected using predictive biomarkers identified via blood-based assays.
This disclosure relates generally to multi-class multi-label classification and more particularly to contradiction avoided learning for multi-class multi-label classification. Conventional classification methods do not consider contradictory outcomes in multi-label classification tasks wherein contradictory outcomes have significant negative impact in the classification problem solution. The present disclosure provides a contradiction avoided learning multi-class multi-label classification. The disclosed method utilizes a binary contradiction matrix constructed using domain knowledge. Based on the binary contradiction matrix the training dataset is divided into two parts, one comprising contradictions and the second without contradictions. The classification model is trained using the divided datasets using a contradiction loss and a binary cross entropy loss to avoid contradictions during learning of the classification model. The disclosed method is used for electrocardiogram classification, shape classification and so on.
Retrospective cohort of patients who underwent conventional surgery between 2018 and 2021. Confirmed gross total resection (removal of 100 % of contrast-enhancing tumor).